Vafidemstat
 | |
| Clinical data | |
|---|---|
| Other names | ORY-2001; ORY2001 |
| Routes of administration | Oral[1][2] |
| Drug class | Lysine-specific demethylase 1 (LSD1) inhibitor; Monoamine oxidase B (MAO-B) inhibitor[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H20N4O2 |
| Molar mass | 336.395 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vafidemstat (INN; developmental code name ORY-2001) is a dual inhibitor of the enzymes lysine-specific demethylase 1 (LSD1; KDM1A) and monoamine oxidase B (MAO-B) which is under development for the treatment of a variety of medical conditions, including aggression, Alzheimer's disease, borderline personality disorder, multiple sclerosis, acute respiratory disease in COVID-19 infection, and schizophrenia.[1][3][2] It is or was also being developed for several other indications, but no recent development has been reported for these uses.[1] The drug is taken by mouth.[1]
As of October 2024, vafidemstat is in phase 2 clinical trials for aggression, Alzheimer's disease, borderline personality disorder, multiple sclerosis, COVID-19 acute respiratory disease, and schizophrenia.[1] Conversely, no recent development has been reported for autism, dementia, Huntington's disease, Parkinson's disease, and telomeric 22q13 monosomy syndrome.[1] It is being developed by Oryzon.[1][3]
Other LSD1 inhibitors that are under development for medical use include bomedemstat (IMG-7289), iadademstat (ORY-1001), phenelzine (Nardil), pulrodemstat (CC-90011), seclidemstat (SP-2577), and tranylcypromine (Parnate).[2][4] Another drug, zavondemstat (QC8222, TACH101), is a pan-inhibitor of lysine-specific demethylase 4 (LSD4; KDM4).[5][6][7] Vafidemstat contains the chemical structure of (1S,2R)-tranylcypromine within its own structure.[8]
References
- ^ a b c d e f g h "Vafidemstat - Oryzon Genomics". AdisInsight. 9 October 2024. Retrieved 6 November 2024.
- ^ a b c Noce B, Di Bello E, Fioravanti R, Mai A (2023). "LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials". Front Pharmacol. 14: 1120911. doi:10.3389/fphar.2023.1120911. PMC 9932783. PMID 36817147.
- ^ a b "Delving into the Latest Updates on Vafidemstat with Synapse". Synapse. 1 November 2024. Retrieved 6 November 2024.
- ^ Johnson JD, Alejo S, Jayamohan S, Sareddy GR (2023). "Lysine-specific demethylase 1 as a therapeutic cancer target: observations from preclinical study". Expert Opin Ther Targets. 27 (12): 1177–1188. doi:10.1080/14728222.2023.2288277. PMC 10872912. PMID 37997756.
- ^ Chandhasin, C., Perabo, F., Dai, Y., DiMascio, L., Mehta, R. K., Hassan, M. K., & Nyati, M. K. (2024). 245 (PB233): Histone methylation changes of H3K9 and H3K36 in PBMCs as pharmacodynamic biomarkers for Zavondemstat (TACH101), a paninhibitor of KDM4 histone lysine demethylase. European Journal of Cancer, 211, 114763.
- ^ "Delving into the Latest Updates on Zavondemstat with Synapse". Synapse. 1 November 2024. Retrieved 6 November 2024.
- ^ World Health Organization (2024). "Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024" (PDF). World Health Organization. p. 184. Retrieved 21 October 2024.
-stat- or enzyme inhibitors -stat [...] -demstat lysine-specific histone demethylase inhibitors (a) bomedemstat (122), iadademstat (119), pulrodemstat (124), seclidemstat (118), vafidemstat (119), zavondemstat (128)
- ^ "Vafidemstat". PubChem. Retrieved 7 November 2024.